Strain Data Sheet
Data update: Aug 20, 2019
Health Report   PCR Protocol   Thawing Method
embryos / sperm >
  Mouse Marking
RBRC No. RBRC01707  
Type TransgeneCartagena  
Species Mus musculus  
Strain name B6.Cg-Tg(Mt1-RET)192Ina  
Former Common name 192 RET  
H-2 Haplotype No Data  
Background strain No Data  
 1 Appearance No Data  
Genotype No Data  
Strain development Developed by Masashi Kato, Nagoya University Graduate School of Medicine. The transgene was injected into the pronuclei of (BALB/c x C57BL/6) x BALB/c fertilized eggs. C57BL/6 and BALB/c mixed background.  
Strain description This strain expresses the human RET gene under the control of the mouse Mt1 promoter/enhancer. This Mt1-RET 192 line develops benign tumors 100% within several months after birth. However they never transform to malignant tumors. Crossing with C57BL/6 multiple times makes this strain more difficult to maintain because of the earlier onset of tumors.  
Colony maintenance Carrier x Noncarrier  
Health Report
Gene Details
Promoter No Data  
 1 Symbol Tg(Mt1-RET)192Ina  
Symbol name transgene insertion 192, Izumi Nakashima  
Chromosome UN  
Common name Tg(Mt1-RET)192Num, Tg(Mt1-RFP/RET)192Num  
Symbol description No Data  
 2 Symbol No Data  
Symbol name SV40 splicing signal-polyadenylation site  
Chromosome UN  
Common name No Data  
Symbol description No Data  
Promoter mouse metallothionein 1 promoter/enhancer  
 3 Symbol RET  
Symbol name recombinant RET proto-oncogene (human)  
Chromosome UN  
Common name RET51, RET9  
Symbol description No Data  
References EMBO J. 1991 Nov;10(11):3167-75.  
Aberrant melanogenesis and melanocytic tumour development in transgenic mice that carry a metallothionein/ret fusion gene.
Research applications Cancer Research,
Dermatology Research,
Mouse Models for Human Disease  
Specific Term and Conditions The following terms and conditions will be requested by the DEPOSITOR.
The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR.
The RECIPIENT of BIOLOGICAL RESOURCE must obtain a prior written consent on use of it from the DEPOSITOR/DEVELOPER. The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use with the results from the use of the BIOLOGICAL RESOURCE. The RECIPIENT agrees to use this BIOLOGICAL RESOURCE as a collaboration with the DEPOSITOR.  
Additional information
 1 Lab HP  
 2 Genotyping protocol <PCR>  
Depositor Kato, Masashi (Chubu University College of Life and Health Sciences)  Kato, Masashi 
Strain Status /
(Expected delivery)

back Back
RIKEN BioResource Research Center

English page click here ANIMAL SEARCH SYSTEM